Although GLP-1 RAs have been suggested to improve endothelial function via anti-inflammatory and antioxidative mechanisms [13], evidence specific to semaglutide in Japanese T2DM patients is limited [8,10]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.